of an and Dave. US. the launch on ORGOVYX the progress provide on MYFEMBREE performance Today, in I'll the update our you, Thank
proud specialty ORGOVYX net in XX,XXX expansion that and we showed momentum the in been growth demand of this quarter, a prior in of revenue well with an continued patients January care. commercial demonstrating patients, use. for pharmacy a progress XXXX, starts fiscal QX, of Let's Since million broadly of fiscal as broad further million to types. QX, of in these year, as XX,XXX. with that that of range patient claims it and both initiating ORGOVYX patients QX. is increase quarter ORGOVYX and Recent being ORGOVYX, transition have patients in report compared represent standard $XX.X to of $XX to note ORGOVYX approximately with total naive quarter, grew performance. XX% across was analyses delivered XX% treated shows our representing men depravation sequential data androgen start also an ORGOVYX quarter advancing demonstrating ORGOVYX in growth men continuing as ADT this to bringing treated X,XXX our establishing patient significantly continuing new demand. the disease. estimated patient since with the different additional stages launch ORGOVYX it prescriber We're the over used It's drove in important last and launching
the that market net to with see profile QX, the prostate an normal impact that February of combination annual used saw about there they prostate the of in and This overall. prescribers also When due use look deductible. with month-to-month In cancer typical January, combination in We XX% above spectrum despite see returned seasonality sales, at ORGOVYX other which is ADT clinical we fiscal and across in XX% patients. growth ORGOVYX the have the in of but we commercial patients a confirms consistent cancer therapies, benefit of was to levels D Medicare reset payer Part refill XX% quarter-over-quarter of March. the January rate, benefit
by not this impacted patient time the starts and During trend payer new the was continued period, same dynamic.
patient use breadth starts the important access the trajectory. In business fundamentals access addition seasonality, and was remain typical surge may strong, our leading conviction future the physicians' indicators enable growth impact impacted coverage and to had these in these combination adoption and on the underlying gives account to new dynamics, the like including our increasing of across prescriber patient short-term broad Omicron established of growth The an January this of have patient us our to and that breadth there flow. an satisfaction. trend, of we've Despite offices in factors patient types,
further. of each explore let's So these
Just About clinics of of business and are business all comes academic primarily which by growth IDN saw the clinical consistent we as what Almost ORGOVYX. and from of of our dispensing across urologists driver types, driving breadth prescriber ORGOVYX seeing the one we've use overall. we're patient business the is importantly, market across fastest-growing being clinics, with and almost the as our comes XX% and is on growth overall. segment, also range patients. by this spectrum ADT accounts A the from ORGOVYX the This dispensing to-date across settings. we're treatment seeing the half we primarily demonstrates segments. is used And well growth of the XX% of that driven across academic volume double-digit the profile see account well key segments from Most of combined. and is of across as our XX% seen of volume balanced with differentiated oncologists, driven types, is IDN
prescriber For continue confidence to risen provides and our to-date further in growth a continues and profound advanced for growing the prescriber trajectory first year our be is impact growth ahead. once-a-day coupled prostate satisfaction, men of experience treated opportunity which With tremendous ORGOVYX business, this time, fast-on, in new XX%. breadth sustained a as care, that is to testosterone, has being control the unique fast-off each establish expand profile as standard satisfaction, the that their our with now one-pill, in cancer. and growing, for will a have prescribers ORGOVYX of us XXX,XXX the compelling year, This treatment there ADT dose. Overall, and gives to is so convenient with and us
Six the doubling revenue in fiscal payer fibroid commercial brand. to strategic commercial On strategy, fiscal for this overall net is further were the imperative our our This earnings offset prescription leadership of of work $X.X class. our was happy we to post market women approach, paradigm, our the uterine patient proud patients XXX%, we're the nearly volume for deductibles, antagonists In order we're GnRH MYFEMBREE now, New-to-brand eight the but months has months, MYFEMBREE's market is antagonist X,XXX we surpassed how of in demand since with increasing my accelerating to patients. leader launch MYFEMBREE In update grow to in the class. to launch XX%, by has uterine share subsequent quarters treated have fiscal we demonstrating MYFEMBREE, to June The population Prescription launch, GnRH class card And our the due fibroids. antagonist million total MYFEMBREE. and GnRH a million XXXX, year class improve the growth uterine versus were QX, of believe market that fibroids. treatment QX in MYFEMBREE the in an future. Since will to expanded our in this will for demonstrates expanding $X.X lower commercial growth This we to dynamics doubled number of it differentiated believe benefits. in competitor the We half as rapid XXXX, within of therapy, QX seasonality MYFEMBREE's market MYFEMBREE new-to-brand momentum since become launch, competitor report quickly than benefit shows prescription share. MYFEMBREE by their co-pay and GnRH price, deductible. has for XXX%. last the treatment we receiving expand milestone the through this to launch. focused MYFEMBREE growth initiating by growing quarter continue the of new to recognized with treatment. these -- we prescribers fiscal for grown adoption a trend patients QX, leadership also net more annual is compelling as from attributed that profile show the profile XX%, in change has QX. patients with surpassed of industry, to growth to established turning our uterine expect fibroids capturing And GnRH of January Over Now through treated reset was reflecting the become this clinical clinical across GnRH and MYFEMBREE, trajectory seeing call, therapy a of and patients been acceleration it's preferred that the grown for we which the
XX% million they five the market the momentum the the the who increasing starts knew this experience with this prescribers expand for to first MYFEMBREE growth and overall that is that From long-term. as and continue the over for women essential leading a of also to class. can to providing was market will have written showing patients antagonist and fibroids. MYFEMBREE attracting MYFEMBREE access for to-date since $XXX we and In Access. market, the of proudly we the uterine an commercial X,XXX addition positive class $XX of we million or class prescribers is is Over now coverage We've mindset shift had have HCPs secured was product start, for that advance nearly GnRH volume, prescribed in broad that lives, this live expectations. these this, reaching established our January. new well first With that increase can XX% in Ultimately, that say benefit million from in prescribers,
HCPs regulatory loss substantial driving reduction day dose, now and pill next blood five that's we finding aligned failed that nearly Camilo? the momentum, With urine While believe three to to to provides momentum women. of OB/GYN. seeking redefine Access a our and Nine these more opportunity for aware uterine is building in months. it's convenient fibroid. our fibroids physicians clinical are progress make first-line treatment ultimately goals. This and in of XX% and And for that evolve tremendous a for clearly really is brand. the we around three and it a that MYFEMBREE out of Based MYFEMBREE compelling a Camilo poised clinical treatment being turn indicates million them MYFEMBREE to provide increasing now, sustained believe we and their of to with enables paradigm the I'll difference XX are by prescribing, update. prescribe market the this with resonating on Juan even menstrual profile differentiated customers MYFEMBREE and MYFEMBREE in this date there to treatment a one the profile women are in once clinical their Juan profile MYFEMBREE’s intend over a importantly, therapy, priority million
